Effect of growth hormone on dawn phenomenon in patients with type 2 diabetes. (2013)

• Record Type: Journal Article
• Authors: Shih, Kuang-Chung; Hsieh, Sheng-Hwu; Kwok, Ching-Fai; Hwu, Chii-Min; Hsieh, Po-Shiuan; Ho, Low-Tone
• Is Part Of: Growth factors. Volume 31:Number 2(2013:Apr.)
• Page Start: 66
• Page End: 73
• Publication Date: 2013
• Subjects: Insulin sensitivity -- dawn phenomenon -- growth hormone -- octreotide -- type 2 diabetes mellitus; Growth factors -- Periodicals; Physiology -- Periodicals; 611
• DOI: 10.3109/08977194.2013.772996
• Languages: English
• ISSNs: 0897-7194

Abstract

Abstract : We aimed to investigate the involvement of growth hormone in dawn phenomenon and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). On six occasions separated by intervals of at least 3 days, subjects received early evening (16:00 hours) or late night (23:00 hours) pretreatment with subcutaneous injection of normal saline, human growth hormone, or octreotide. Modified euglycemic insulin clamp test was done 16 hours later and variable glucose infusion (M values) was determined. Plasma glucose, serum insulin, insulin-like growth factor-1, non-esterified fatty acids, and metabolic clearance rate of insulin (MCRI) were measured. Early evening application of growth hormone decreased MCRI 16 hours later, suggesting reduction in insulin sensitivity. Exogenous growth hormone injection reduced insulin sensitivity in T2DM patients. Results provide direct evidence for the role of growth hormone in regulating the insulin sensitivity in insulin-resistant patients.